A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.